Real world experience in low-dose ipilimumab in combination with PD-1 blockade in advanced melanoma patients

Dual immune-checkpoint blockade with the anti-PD-1 antibody nivolumab (1 mg/kg) and standard-dose ipilimumab (3 mg/kg) is the mainstay of immunotherapy in advanced melanoma and it is approved since 2016. However, severe side effects (grade 3/4) occur in up to 60% of the patients. Recently, clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Kirchberger, Michael Constantin, Moreira, Alvaro, Erdmann, Michael, Schuler, Gerold, Heinzerling, Lucie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034742/
https://www.ncbi.nlm.nih.gov/pubmed/29988983
http://dx.doi.org/10.18632/oncotarget.25627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034742/
https://www.ncbi.nlm.nih.gov/pubmed/29988983
http://dx.doi.org/10.18632/oncotarget.25627

Ejemplares similares